OncoSec, USF Research Foundation deal

The not-for-profit granted OncoSec an exclusive license to IP related to the delivery of gene-based therapeutics via intratumoral and intramuscular electroporation. OncoSec said the deal extends the patent protection for the company's ImmunoPulse therapy to 2024. Financial terms were not disclosed.

ImmunoPulse uses OncoSec's OMS ElectroImmunotherapy electroporation device, which applies a brief electric field skin to temporarily open pores in the cell membrane, to deliver DNA IL-12 and allow the plasmid coding for IL-12 to be absorbed more efficiently. IL-12 activates and increases the level of circulating macrophages and cytotoxic T cells, and stimulates the immune system. The ImmunoPulse therapy is in Phase II testing for metastatic melanoma, Merkel cell carcinoma and cutaneous T cell lymphoma (CTCL). ...